Understanding Melasma: Hormonal Triggers, Clinical Treatment Approaches, and Long-Term Management

Melasma is a chronic pigmentation condition primarily triggered by hormonal fluctuations (pregnancy, contraceptives, hormone therapy), UV exposure, and genetic predisposition. It presents as symmetrical brown patches on the face and requires multi-modal treatment combining sun protection, topical depigmenting agents, and hormonal consideration for effective long-term management.

Melasma presents as symmetrical patches of brown to grey-brown pigmentation, typically across the cheeks, forehead, upper lip, and chin. Unlike other forms of hyperpigmentation that respond predictably to treatment, melasma follows a frustratingly cyclical pattern of improvement and recurrence. This chronic condition affects predominantly women during their reproductive years, with hormonal fluctuations serving as the primary catalyst for melanocyte activation.

What distinguishes melasma from other pigmentation concerns is its complex aetiology. Whilst UV exposure certainly exacerbates the condition, the fundamental trigger lies deeper within the endocrine system. Oestrogen and progesterone fluctuations during pregnancy, contraceptive use, or hormone replacement therapy stimulate melanocytes in genetically susceptible individuals, creating pigmentation that extends beyond the epidermis into the dermal layer in many cases. This depth complicates treatment and explains why surface-level approaches often prove insufficient.

Understanding melasma requires recognising it as a multifactorial condition where hormones, genetics, UV exposure, visible light, and even heat converge to create persistent pigmentation. As discussed in our comprehensive guide to layered pigmentation treatment approaches, addressing melasma demands a multi-modal strategy rather than reliance on a single ingredient. The condition’s hormonal foundation means that even the most sophisticated topical regimen may prove inadequate without addressing the underlying endocrine triggers.

In clinical practice, Dr Alek observes that patients with melasma often arrive having tried numerous “miracle” brightening products with minimal success. This frustration stems from a fundamental misunderstanding: melasma is not simply excess pigment that can be bleached away. It represents a chronic activation of melanocytes driven by internal hormonal signals, requiring a bespoke treatment approach that addresses both the visible pigmentation and the biological mechanisms perpetuating it. Your skin journey with melasma is necessarily long-term, focusing on management rather than cure, with realistic expectations about improvement timelines and the likelihood of recurrence.

The Hormonal Cascade: How Oestrogen and Progesterone Activate Melasma

Melanocytes, the pigment-producing cells in the basal layer of the epidermis, possess receptors for both oestrogen and progesterone. When hormone levels fluctuate, these receptors trigger increased melanin synthesis through a cascade of biochemical signals. Oestrogen specifically upregulates tyrosinase activity, the rate-limiting enzyme in melanin production, whilst progesterone appears to enhance melanocyte sensitivity to UV radiation. This explains why melasma typically emerges or intensifies during periods of hormonal change rather than remaining constant throughout a woman’s life.

Cysteo™ Cream

The relationship between hormones and pigmentation is not linear. Research suggests that it is the fluctuation in hormone levels, rather than absolute concentrations, that proves most problematic for melasma development. This is why melasma often appears during the second or third trimester of pregnancy when hormone levels are rising rapidly, or when starting or stopping hormonal contraceptives when levels shift dramatically.

Pregnancy-Induced Melasma: The Chloasma Pattern

Melasma gravidarum, historically termed chloasma or “the mask of pregnancy”, affects between 50 and 70 per cent of pregnant women, particularly those with Fitzpatrick skin types III to V. The condition typically manifests during the second trimester when oestrogen and progesterone levels surge to support foetal development. The characteristic distribution follows a centrofacial pattern, with pigmentation concentrated on the forehead, cheeks, nose, and upper lip, creating the distinctive “mask” appearance.

Pregnancy represents a perfect storm for melasma development. Beyond the dramatic hormonal shifts, pregnant women experience increased skin temperature, enhanced blood flow to facial tissues, and often heightened photosensitivity. These factors combine to create an environment where melanocytes become hyperactive and responsive to even minimal UV exposure. Many women report that their melasma darkens noticeably after brief sun exposure that previously caused no pigmentation concerns.

The prognosis for pregnancy-related melasma varies considerably. In clinical consultation, Dr Alek notes that approximately one-third of cases resolve spontaneously within the first year postpartum as hormone levels normalise. Another third improve partially but do not completely clear, whilst the remaining third persist unchanged or worsen with subsequent pregnancies. This variability reflects individual genetic susceptibility and the depth of pigment deposition, factors that cannot be reliably predicted at onset.

Treatment during pregnancy requires particular caution. Many effective depigmenting agents, including hydroquinone and retinoids, are contraindicated during pregnancy and breastfeeding. This leaves pregnant women with limited options beyond rigorous sun protection and gentle topical agents such as azelaic acid and vitamin C. The focus during pregnancy should be on preventing worsening rather than expecting significant improvement, with more aggressive treatment reserved for the postpartum period.

Contraceptive-Related Pigmentation: Combined Oral Contraceptives and Melasma Risk

Combined oral contraceptives containing both oestrogen and progestogen carry a well-documented association with melasma development. Studies indicate that between 10 and 25 per cent of women taking combined contraceptives develop some degree of facial pigmentation, with risk increasing with duration of use. The mechanism mirrors pregnancy-induced melasma: synthetic hormones activate melanocyte receptors, increasing pigment production in genetically susceptible individuals.

Not all contraceptive formulations carry equal risk. Combined pills with higher oestrogen content appear more likely to trigger melasma than lower-dose formulations. Progestogen-only preparations, including the mini-pill, implants, and hormonal IUDs, demonstrate lower melasma risk, though they are not entirely without concern. Some progestogens possess androgenic properties that may paradoxically protect against melasma by counteracting oestrogen’s melanogenic effects.

The decision to discontinue hormonal contraception due to melasma requires careful consideration of the broader clinical context. Whilst stopping the pill may improve pigmentation in some cases, the response is unpredictable and often incomplete. Many women find that their melasma persists despite contraceptive cessation, suggesting that the hormonal trigger initiated a chronic process that continues independently. Dr Alek’s approach emphasises discussing alternative contraceptive options with the prescribing physician rather than abruptly discontinuing hormonal contraception, particularly when it serves important therapeutic purposes beyond pregnancy prevention.

Hormone Replacement Therapy and Perimenopausal Melasma

Hormone replacement therapy, particularly formulations containing synthetic oestrogens, can trigger melasma in postmenopausal women. This presents a clinical dilemma: the same hormones that alleviate menopausal symptoms may simultaneously worsen facial pigmentation. Women who developed melasma during pregnancy or whilst taking contraceptives face higher risk of recurrence when starting HRT.

Perimenopausal hormone fluctuations themselves can trigger melasma even without HRT. The erratic oestrogen levels characteristic of perimenopause create the hormonal instability that activates melanocytes. Some women develop melasma for the first time in their late forties or early fifties, attributing it incorrectly to “age spots” when the true cause is hormonal fluctuation.

DERMACEUTIC Mela Cream

Transdermal oestrogen preparations may carry lower melasma risk than oral formulations, though evidence remains limited. The rationale centres on avoiding the hepatic first-pass metabolism that occurs with oral oestrogen, which generates metabolites that may be particularly melanogenic. For women requiring HRT who develop melasma, working with their gynaecologist to adjust formulation, dose, or delivery method may prove beneficial before abandoning hormone therapy entirely.

The Cortisol Connection: Stress Hormones and Pigmentation Intensity

Chronic stress exacerbates melasma through cortisol-mediated pathways. Elevated cortisol stimulates melanocyte-stimulating hormone (MSH) production, which directly activates melanin synthesis. This explains clinical observations that melasma often intensifies during periods of significant life stress, even when other variables such as sun exposure remain constant.

The stress-pigmentation connection extends beyond cortisol. Chronic stress impairs skin barrier function, increases inflammatory mediators, and may enhance UV sensitivity, creating a biological environment conducive to pigmentation. In practice, patients managing high-stress periods often report that their melasma darkens noticeably, improving somewhat when stress resolves, though rarely returning to baseline without targeted treatment.

MESOESTETIC Cosmelan 2

Addressing stress as part of melasma management is not merely psychological support, it represents genuine biological intervention. Whilst stress reduction alone will not clear melasma, it constitutes an important component of comprehensive management. Dr Alek’s clinical framework acknowledges that skincare exists within the broader context of overall health, where sleep quality, stress management, and hormonal balance collectively influence treatment outcomes.

Clinical Patterns and Diagnostic Assessment: Identifying Your Melasma Type

Melasma presents in characteristic distribution patterns that provide diagnostic clues and prognostic information. Recognising these patterns helps clinicians predict treatment response and set realistic expectations for improvement. The three primary distribution patterns are centrofacial, malar, and mandibular, each with distinct characteristics and treatment considerations.

Accurate diagnosis requires distinguishing melasma from other pigmentation disorders that may present similarly. Post-inflammatory hyperpigmentation, solar lentigines, and drug-induced pigmentation can mimic melasma, but differ fundamentally in aetiology and treatment approach. Clinical history, particularly regarding hormonal triggers and pattern of onset, provides essential diagnostic information that guides appropriate management.

Centrofacial, Malar, and Mandibular Distribution Patterns

Centrofacial melasma, the most common pattern affecting approximately 50 to 80 per cent of cases, involves the forehead, cheeks, upper lip, nose, and chin. This distribution creates the classic “mask of pregnancy” appearance. The pigmentation is typically symmetrical, with fairly well-defined borders that follow the contours of facial anatomy. Centrofacial melasma often correlates with hormonal triggers, particularly pregnancy and oral contraceptives.

Malar melasma affects the cheeks and nose, sparing the upper lip and forehead. This pattern accounts for approximately 20 per cent of cases and may have a stronger association with UV exposure than hormonal factors alone. The pigmentation in malar melasma often appears more diffuse and less sharply demarcated than centrofacial patterns, blending gradually into surrounding skin.

Mandibular melasma, the least common pattern affecting fewer than 10 per cent of cases, involves the jawline and mandibular area. This distribution may relate to external factors such as cosmetic application, heat exposure from cooking, or phototoxic reactions. Mandibular melasma sometimes proves more resistant to treatment, possibly reflecting the mixed aetiology involving both hormonal and environmental triggers.

Understanding distribution patterns helps predict treatment response. Centrofacial melasma with clear hormonal triggers often responds well to combined topical therapy once hormonal factors are addressed. Malar patterns may require more aggressive photoprotection given the UV component. Mandibular melasma benefits from careful evaluation of potential external triggers that may perpetuate pigmentation despite appropriate treatment.

Epidermal vs Dermal vs Mixed Melasma: Why Depth Matters for Treatment

Melasma is classified by pigment depth as epidermal, dermal, or mixed, a distinction with profound treatment implications. Epidermal melasma, where excess melanin resides in the epidermis, responds best to topical depigmenting agents that can reach and influence melanocytes in the basal layer. Dermal melasma, where melanin has deposited in the dermis after being released from damaged keratinocytes, proves significantly more treatment-resistant because topical agents cannot effectively penetrate to dermal depths.

Mixed melasma, the most common form affecting approximately 60 per cent of cases, contains both epidermal and dermal pigment. Treatment of mixed melasma typically achieves partial improvement as the epidermal component responds whilst the dermal component persists. This explains why many patients experience initial improvement followed by a plateau, with residual pigmentation that proves stubbornly resistant to further topical treatment.

The biological explanation for dermal pigment deposition involves melanin incontinence. Chronic epidermal melasma causes damage to basal keratinocytes, which release melanin into the dermis where it is engulfed by dermal macrophages called melanophages. This dermal melanin cannot be influenced by topical depigmenting agents that target melanocyte activity, as it no longer resides within melanocytes but rather within immune cells in the dermis.

Dermal pigment depth explains why melasma often appears grey-brown rather than purely brown. The Tyndall effect, where light scattering by dermal melanin produces a blue-grey hue, creates the characteristic ashen quality of deep melasma. This grey tone serves as a clinical indicator of dermal involvement and suggests that treatment expectations should be modest, focusing on preventing further darkening and improving epidermal pigmentation whilst accepting that some residual discolouration may persist.

Wood’s Lamp Examination: Determining Pigment Depth in Clinical Practice

Wood’s lamp examination, using ultraviolet light at 340 to 400 nanometres, helps determine pigment depth by enhancing the contrast of epidermal pigmentation whilst dermal pigment appears unchanged or less prominent. In a darkened room, epidermal melasma appears darker and more defined under Wood’s lamp, whilst dermal melasma shows minimal enhancement. Mixed melasma demonstrates variable enhancement across affected areas, indicating regions of different pigment depth.

This diagnostic information guides treatment planning and expectation setting. When Wood’s lamp examination reveals predominantly epidermal pigmentation with significant enhancement, patients can be counselled that topical therapy has good potential for meaningful improvement. Conversely, when pigmentation shows minimal Wood’s lamp enhancement, indicating dermal involvement, expectations should be adjusted accordingly, with emphasis on maintenance and prevention rather than complete clearance.

Wood’s lamp examination is not infallible. Skin inflammation, recent sun exposure, and certain skincare products can affect results. The examination provides useful information but should be interpreted within the broader clinical context rather than as a definitive predictor of treatment response. In clinical consultation, Dr Alek uses Wood’s lamp findings as one component of assessment, alongside distribution pattern, hormonal history, and previous treatment response, to develop a bespoke management strategy.

Beyond UV Exposure: The Complete Spectrum of Melasma Triggers

Whilst UV radiation remains the most widely recognised melasma trigger, a comprehensive understanding requires acknowledging the complete spectrum of factors that activate and perpetuate this condition. Genetic predisposition determines who develops melasma when exposed to hormonal and environmental triggers. Heat and visible light, factors often overlooked in conventional sun protection advice, play significant roles in melasma activation. Certain medications and cosmetic ingredients can photosensitise skin or directly stimulate melanocytes, exacerbating pigmentation.

Genetic Predisposition: Why Fitzpatrick Types III-V Experience Higher Incidence

Melasma demonstrates clear ethnic and genetic patterns. Individuals of Latin American, Asian, Middle Eastern, and African descent experience significantly higher melasma incidence than those of Northern European ancestry. Fitzpatrick skin types III to V, characterised by olive to brown baseline skin tone, show the greatest susceptibility. This genetic predisposition reflects differences in melanocyte activity, with darker skin types possessing melanocytes that are more numerous, larger, and more metabolically active.

Family history serves as a strong predictor of melasma risk. Studies indicate that between 30 and 50 per cent of individuals with melasma report affected family members, suggesting inherited genetic variants that influence melanocyte behaviour. These genetic factors likely involve multiple genes controlling melanin synthesis, melanosome transfer, and melanocyte response to hormonal and environmental triggers.

The genetic component explains why some women develop severe melasma during their first pregnancy whilst others with identical hormonal profiles experience no pigmentation. It also clarifies why melasma persists in some individuals despite removal of obvious triggers, whilst others see spontaneous resolution. Your genetic makeup determines your melanocyte reactivity, establishing the threshold at which hormonal and environmental factors will trigger visible pigmentation.

Understanding the genetic basis of melasma helps frame realistic expectations. Individuals with strong family history and darker skin types should anticipate that melasma, once triggered, may prove chronic and require long-term management rather than representing a temporary condition that will resolve completely with short-term treatment. This knowledge allows for early intervention and consistent photoprotection to minimise severity.

Heat and Infrared Radiation: The Overlooked Environmental Factor

Heat exposure independently triggers melasma, separate from UV radiation. This explains clinical observations that melasma often worsens in summer even with diligent sun protection, and why individuals working in hot environments such as kitchens develop facial pigmentation. Heat increases skin temperature, which stimulates melanocyte activity through temperature-sensitive biochemical pathways. Research suggests that even modest temperature elevation of 1 to 2 degrees Celsius can enhance melanin production.

Infrared radiation, comprising approximately 50 per cent of solar radiation, penetrates deeply into skin and generates heat. Whilst broad-spectrum sunscreens block UV radiation, they provide minimal protection against infrared. This creates a scenario where individuals using excellent sun protection still experience melasma worsening due to unprotected heat and infrared exposure. The South African climate, with intense sun and high ambient temperatures, creates particular challenges for melasma management.

Practical heat protection requires strategies beyond sunscreen. Seeking shade during peak heat hours, using cooling facial mists, avoiding hot environments when possible, and wearing wide-brimmed hats that provide shade reduce facial skin temperature. Some specialised sunscreens now incorporate iron oxides, which reflect infrared radiation and visible light, offering more comprehensive protection than traditional UV filters alone. Formulations such as those in SkinMiles’ curated sun protection range that include iron oxides support more complete photoprotection for melasma-prone skin.

Visible light, particularly high-energy visible (HEV) or blue light, also contributes to melasma. This wavelength range, between 400 and 500 nanometres, penetrates deeply and stimulates melanin production, particularly in darker skin types. Standard sunscreens provide no protection against visible light. Mineral sunscreens containing titanium dioxide and zinc oxide offer some visible light protection, but tinted formulations with iron oxides provide superior defence by physically blocking this wavelength range.

Phototoxic Medications and Cosmetic Ingredients That Exacerbate Melasma

Certain medications increase photosensitivity and melasma risk. Tetracycline antibiotics, non-steroidal anti-inflammatory drugs, thiazide diuretics, and some antiepileptic medications can trigger phototoxic reactions that worsen pigmentation. These medications do not directly cause melasma but lower the threshold at which UV exposure triggers melanin production, effectively amplifying the impact of sun exposure.

Cosmetic ingredients require careful consideration in melasma-prone individuals. Whilst vitamin C and niacinamide support skin health and help reduce the appearance of pigmentation, certain essential oils and fragrance compounds can photosensitise skin. Bergamot oil, for instance, contains psoralens that dramatically increase UV sensitivity. Even beneficial ingredients such as retinoids and alpha hydroxy acids, whilst supporting cell turnover, temporarily increase photosensitivity and require meticulous sun protection during use.

The concept of phototoxicity versus photoallergy is important. Phototoxic reactions occur predictably when sufficient drug concentration combines with adequate UV exposure, affecting anyone given the right